These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 35928724)

  • 1. Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study.
    Xu C; Yan L; An Q; Zhang S; Guan X; Wang Z; Lv A; Liu D; Liu F; Dong B; Zhao M; Tian X; Hao C
    Int J Med Sci; 2022; 19(8):1241-1253. PubMed ID: 35928724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
    Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N
    J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and genetically characterization of patient-derived xenograft models of cervical cancer.
    Zou S; Ye M; Zhang JA; Ji H; Chen Y; Zhu X
    BMC Med Genomics; 2022 Sep; 15(1):191. PubMed ID: 36076209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing.
    Cornillie J; Wozniak A; Li H; Wang Y; Boeckx B; Gebreyohannes YK; Wellens J; Vanleeuw U; Hompes D; Stas M; Sinnaeve F; Wafa H; Lambrechts D; Debiec-Rychter M; Sciot R; Schöffski P
    Mol Cancer Ther; 2019 Jun; 18(6):1168-1178. PubMed ID: 30962320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models.
    Okada S; Vaeteewoottacharn K; Kariya R
    Cells; 2019 Aug; 8(8):. PubMed ID: 31412684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model.
    Oda Y; Niimi K; Yoshida K; Tamauchi S; Yokoi A; Yasui Y; Nishiko Y; Shibata M; Shimizu Y; Yoshihara M; Ikeda Y; Yoshikawa N; Nishino K; Yamamoto E; Kajiyama H
    BMC Cancer; 2023 Nov; 23(1):1103. PubMed ID: 37957624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt/mTOR/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance.
    Zhang S; Yan L; Cui C; Wang Z; Wu J; Lv A; Zhao M; Dong B; Zhang W; Guan X; Tian X; Hao C
    Onco Targets Ther; 2020; 13():6523-6537. PubMed ID: 32753891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tsp2 Facilitates Tumor-associated Fibroblasts Formation and Promotes Tumor Progression in Retroperitoneal Liposarcoma.
    Xu C; Yan L; Guan X; Wang Z; Wu J; Lv A; Liu D; Liu F; Dong B; Zhao M; Jia L; Tian X; Hao C
    Int J Biol Sci; 2022; 18(13):5038-5055. PubMed ID: 35982904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
    Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q
    Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.
    Chen Y; Zhang R; Wang L; Correa AM; Pataer A; Xu Y; Zhang X; Ren C; Wu S; Meng QH; Fujimoto J; Jensen VB; Antonoff MB; Hofstetter WL; Mehran RJ; Pisimisis G; Rice DC; Sepesi B; Vaporciyan AA; Walsh GL; Swisher SG; Roth JA; Heymach JV; Fang B
    Cancer; 2019 Nov; 125(21):3738-3748. PubMed ID: 31287557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
    Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma.
    Choi B; Lee JS; Kim SJ; Hong D; Park JB; Lee KY
    Cancer Lett; 2020 May; 478():56-69. PubMed ID: 32145342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma.
    Yan L; Wang Z; Cui C; Guan X; Dong B; Zhao M; Wu J; Tian X; Hao C
    Cancer Sci; 2019 Oct; 110(10):3038-3048. PubMed ID: 31385405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degree of
    Bill KLJ; Seligson ND; Hays JL; Awasthi A; Demoret B; Stets CW; Duggan MC; Bupathi M; Brock GN; Millis SZ; Shakya R; Timmers CD; Wakely PE; Pollock RE; Chen JL
    Oncologist; 2019 Jul; 24(7):989-996. PubMed ID: 31019022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity.
    Chen X; Shen C; Wei Z; Zhang R; Wang Y; Jiang L; Chen K; Qiu S; Zhang Y; Zhang T; Chen B; Xu Y; Feng Q; Huang J; Zhong Z; Li H; Che G; Xiao K
    Cancer Biol Med; 2021 Feb; 18(1):184-198. PubMed ID: 33628593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence.
    Zhang S; Yan L; Cui C; Wang Z; Wu J; Zhao M; Dong B; Guan X; Tian X; Hao C
    Oncol Rep; 2020 Aug; 44(2):565-576. PubMed ID: 32627015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
    Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
    J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
    Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
    Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts.
    Kuwata T; Yanagihara K; Iino Y; Komatsu T; Ochiai A; Sekine S; Taniguchi H; Katai H; Kinoshita T; Ohtsu A
    Cells; 2019 Jun; 8(6):. PubMed ID: 31207870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.
    Kanaya N; Somlo G; Wu J; Frankel P; Kai M; Liu X; Wu SV; Nguyen D; Chan N; Hsieh MY; Kirschenbaum M; Kruper L; Vito C; Badie B; Yim JH; Yuan Y; Hurria A; Peiguo C; Mortimer J; Chen S
    J Steroid Biochem Mol Biol; 2017 Jun; 170():65-74. PubMed ID: 27154416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.